The effect of synbiotic consumption on serum paraoxonase 1(PON1), Soluble CD163/Soluble TNF-like weak inducer of apoptosis(sCD163/sTWEAK) and lipid profile in patients with chronic heart failure

Iran University of Medical Sciences0 个研究点目标入组 90 人开始时间: 待定最近更新: 2020年11月30日

适应症

试验速览

暂无简介。

•Age range from 30 to 70 yearsPatients with systolic heart failure (LVEF <40%) approved by a cardiologist and receiving at least 3 months of standard heart failure treatment , Medications have reached the maximum tolerated dose and their medication dose will remain constant throughout the study.class 1,2 and 3 of NYHA classificationWillingness to participate in the study and sign informed written consentLack of other diseases including chronic and acute liver disorders (hepatitis B, C, etc.), diabetes, thyroid disorders, severe renal dysfunction (300 mmol /l = creatinine ), pulmonary diseases, inflammatory and autoimmune diseases, Cancer, acute infectionNot using any nutritional supplements for the past two months.No substance abuse and smokingNot taking Corticosteroids in the past 4 weeksFailure to receive antibiotics in the past 3 monthsNo history of gastrointestinal surgeryNo anti-inflammatory drugs except low-dose aspirin (one 80 mg daily)No artificial heart valveNo history of rheumatic heart diseaseNot being pregnant and breastfeedingLack of insulin BMI< 30

•Not willing to continue cooperationuse of less than 80% of supplements given to the patient during the study period Acceptance rate = The number of capsules given to the patient - the Number of capsules not used / The number of capsules given to the patientother disease such as metabolic diseases,Cancer and inflammatory diseases during the study that Need special treatment or antibiotic use.Changes in the type and dose of drug which is using by the patient .

发起方